Teva Pharmaceutical Industries (TEVA) Could Be 10% Undervalued After FDA Accepted Ecopipam NDA

Simply Wall St.08-25 20:28

Teva Pharmaceutical Industries (NYSE:TEVA) is back in focus after the U.S. Food and Drug Administration accepted its New Drug Application for ecopipam, an investigational pediatric Tourette syndrome ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2662581730?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/308047-main-header/1585187365850","is_english":true,"pubTime":"2026-08-25 20:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2662581730","market":"us","top_or_hot":-1,"title":"Teva Pharmaceutical Industries (TEVA) Could Be 10% Undervalued After FDA Accepted Ecopipam NDA","media":"Simply Wall St.","content":"<div>\n<p>Teva Pharmaceutical Industries (NYSE:TEVA) is back in focus after the U.S. Food and Drug Administration accepted its New Drug Application for ecopipam, an investigational pediatric Tourette syndrome ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-teva/teva-pharmaceutical-industries/news/teva-pharmaceutical-industries-teva-could-be-10-undervalued\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Teva Pharmaceutical Industries (TEVA) Could Be 10% Undervalued After FDA Accepted Ecopipam NDA</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTeva Pharmaceutical Industries (TEVA) Could Be 10% Undervalued After FDA Accepted Ecopipam NDA\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-08-25 20:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-teva/teva-pharmaceutical-industries/news/teva-pharmaceutical-industries-teva-could-be-10-undervalued><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Teva Pharmaceutical Industries (NYSE:TEVA) is back in focus after the U.S. Food and Drug Administration accepted its New Drug Application for ecopipam, an investigational pediatric Tourette syndrome ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-teva/teva-pharmaceutical-industries/news/teva-pharmaceutical-industries-teva-could-be-10-undervalued\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TEVA","symbol_name":"梯瓦制药","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-teva/teva-pharmaceutical-industries/news/teva-pharmaceutical-industries-teva-could-be-10-undervalued","article_id":"2662581730","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/308047-main-header/1585187365850"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-teva/teva-pharmaceutical-industries/news/teva-pharmaceutical-industries-teva-could-be-10-undervalued","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2662581730","pubTimestamp":1787660886,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Teva Pharmaceutical Industries (NYSE:TEVA) is back in focus after the U.S. Food and Drug Administration accepted its New Drug Application for ecopipam, an investigational pediatric Tourette syndrome treatment with Orphan Drug status.\nSee our latest analysis for Teva Pharmaceutical Industries.\nThe ecopipam news lands after a strong run for Teva Pharmaceutical Industries, with a 30 day share price return of 19.86% and a 1 year total shareholder return of 103.81% that signals building momentum...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"TEVA":"梯瓦制药","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LABU":"三倍做多标普生物-Direxion","BK4596":"哈里斯概念","BK4559":"巴菲特持仓","BK4007":"制药","BK4566":"资本集团","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","BK4584":"避孕概念","BK4557":"大麻股","BK4588":"碎股","BK4585":"ETF&股票定投概念"},"translate_title":"FDA 接受 Ecopipam NDA 后，梯瓦制药工业公司 (TEVA) 的估值可能被低估 10%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEVA":1.5,"LABU":1.5},"content_text":"Teva Pharmaceutical Industries (NYSE:TEVA) is back in focus after the U.S. Food and Drug Administration accepted its New Drug Application for ecopipam, an investigational pediatric Tourette syndrome treatment with Orphan Drug status. See our latest analysis for Teva Pharmaceutical Industries. The ecopipam news lands after a strong run for Teva Pharmaceutical Industries, with a 30 day share price return of 19.86% and a 1 year total shareholder return of 103.81% that signals building momentum rather than fading enthusiasm. If this kind of specialty treatment story interests you, it can be useful to also look at broader healthcare technology themes and see what is driving other potential opportunities through the 40 healthcare AI stocks For Teva Pharmaceutical Industries, a triple digit 1 year return and fresh excitement around ecopipam raise a basic issue. Are you mainly seeing improving business fundamentals being recognized, or a swing in sentiment that valuation now needs to test? AdvertisementMost Popular Narrative: 9.7% Undervalued On the most followed narrative, Teva Pharmaceutical Industries carries a fair value of $40.90 against a last close of $36.93, which points to some remaining upside that the current price has not fully captured.  Teva's strategic focus and rapid execution on expanding its innovative branded products (AUSTEDO, AJOVY, UZEDY, and upcoming olanzapine LAI), combined with a robust late-stage pipeline targeting large patient populations, are expected to drive higher-margin topline growth and a more profitable product mix, supporting gross margin and net earnings expansion.  Read the complete narrative. Want to see what kind of revenue mix shift and earnings ramp are baked into that fair value. The narrative leans heavily on margin expansion and a future earnings multiple that sits well above the broader pharmaceuticals group. Curious which specific growth and profitability assumptions support that pricing power story. Result: Fair Value of $40.90 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, Teva Pharmaceutical Industries still carries meaningful risks, including heavy net debt around US$15b and dependence on a few key branded drugs that face pricing and execution pressure. Find out about the key risks to this Teva Pharmaceutical Industries narrative. Another View On Teva Pharmaceutical Industries Valuation The first narrative frames Teva Pharmaceutical Industries as about 9.7% undervalued, yet the market is currently paying a steep 61x P/E. That compares with 16.8x for the US pharmaceuticals group and a fair ratio of 35.6x. This gap suggests investors may be paying a premium that could unwind if expectations cool. For a closer look at what the numbers imply about that premium, review the valuation breakdown in the See what the numbers say about this price — find out in our valuation breakdown. NYSE:TEVA P/E Ratio as at Aug 2026Next Steps Seeing both enthusiasm and questions around Teva Pharmaceutical Industries in this article, it makes sense to review the data yourself and decide where you stand. To consider the potential benefits alongside the concerns in a single view, start with these 3 key rewards and 2 important warning signs Looking for more investment ideas beyond Teva Pharmaceutical Industries? If Teva Pharmaceutical Industries has sharpened your interest in focused opportunities, do not stop here. Use structured stock ideas to keep your watchlist working harder.  Target potential mispricings by scanning companies that combine strong fundamentals with attractive pricing through the 49 high quality undervalued stocks. Strengthen your income stream by reviewing companies with robust yields and staying power via the 12 dividend fortresses. Protect your downside by concentrating on companies that score well on resilience using the 74 resilient stocks with low risk scores.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Teva Pharmaceutical Industries might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2662581730","isCrawlerRequest":true}